Articles about Impel NeuroPharma

Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines

The U.S. Food and Drug Administration has approved Impel NeuroPharma’s Trudhesa to treat migraine headaches, the Seattle company announced Friday.… Read More

The voters will see you now: The finalists for Health Innovation of the Year at the GeekWire Awards

The greater Seattle area is a hotbed for health technology and the past year has seen groundbreaking advancements in the… Read More

Seattle biotech firm Impel NeuroPharma files for $75M IPO

Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops drugs for central nervous system disorders… Read More

Tech Moves: Former Oracle exec joins F5 as EVP of global services; Meet Blue Origin’s new CEO; and more

F5 Networks announced in July that its longtime chief operations officer Edward Julian Eames is retiring at the end of… Read More

Tech Moves: Appuri appoints Todd Owens as CEO; Zipwhip adds to leadership; and more

Seattle-based Appuri, a startup using big data in an attempt to predict customer dissatisfaction, has appointed a new CEO: former… Read More

Impel NeuroPharma raises $36M for drug delivery platform that bypasses blood-brain barrier

Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and… Read More